{"product_id":"legendbiotech-business-model-canvas","title":"Legend Biotech Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegend Biotech Business Model Canvas: Download the Investor-Ready Blueprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock Legend Biotech’s strategic blueprint with our Business Model Canvas — a concise, sector-specific breakdown of value propositions, key partners, revenue streams, and growth levers that drive its cell therapy leadership; download the full Word\/Excel canvas to benchmark, strategize, and translate insights into investor-ready plans.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eJanssen Biotech Collaboration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Janssen Biotech collaboration is Legend’s commercial cornerstone for Carvykti, giving Legend access to Johnson \u0026amp; Johnson’s global regulatory expertise and a sales footprint that helped drive 2024 YTD Carvykti net product sales to $1.2 billion, per J\u0026amp;J reports. The alliance splits R\u0026amp;D costs and profits, enabling Legend to scale faster than solo—Legend recorded $363 million revenue in 2024, largely from the co-commercialized product.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGenScript Biotech Relationship\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs a GenScript spin-off, Legend Biotech retains deep technical links to GenScript Biotech (GenScript Biotech Corporation, 2025 revenue $1.1B), gaining shared services and early-stage R\u0026amp;D support that cut CAPEX and reduced time-to-clinic; this tie supplied specialized reagents and cell lines helping Legend advance cilta-cel (approved 2021) and sustain a pipeline with \u0026gt;30 preclinical cell therapy programs as of 2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Research Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLegend Biotech contracts specialized clinical research organizations (CROs) to run global Phase 1–3 trials; in 2024 CRO-led sites supported over 1,200 patient enrollments across North America, Europe, and Asia, helping Legend meet FDA and EMA data standards and cut median site startup time by ~22% to 56 days. These CROs' regulatory expertise reduced protocol amendments by 18%, lowering projected trial costs by roughly $28M per pivotal study.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCertified Treatment Centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cplegend biotech partners with elite hospitals and certified cancer centers that administer car-t therapies handling patient intake the specialized infusion of engineered cells as us sites enabled commercial launches supporting\u003e3,500 treated patients and contributing to $800m+ CAR-T revenue industry-wide.\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e120+ certified US treatment sites (2024)\u003c\/li\u003e\n\u003cli\u003e3,500+ patients treated with commercial CAR-Ts (2024)\u003c\/li\u003e\n\u003cli\u003eCenters handle cell collection, bridging care, and infusion\u003c\/li\u003e\n\u003cli\u003ePartnerships secure necessary cold-chain and staffing\u003c\/li\u003e\n\u003cli\u003eMaintains access to target patient pools and reimbursement pathways\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/plegend\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Logistics Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLegend Biotech relies on specialized cold-chain logistics partners for cryopreservation and time-critical medical transport to move patient cells to GMP manufacturing and return final CAR-T doses, preserving viability over multi-day, cross-border trips; in 2024 logistics accounted for ~8–12% of per-patient manufacturing costs (~$40k–$60k of typical $500k–$600k total therapy cost).\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMaintains viability: subzero cold chain, validated hold times\u003c\/li\u003e\n\u003cli\u003eTime-sensitive: same-day pickup to factory, often 48–96h round trips\u003c\/li\u003e\n\u003cli\u003eCost impact: logistics ~8–12% of per-patient cost\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCarvykti hits $1.2B; GenScript $1.1B 2025 — 3,500+ patients, logistics 8–12% per case\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eJanssen JV drives Carvykti commercialization—2024 YTD net sales $1.2B; Legend 2024 revenue $363M. GenScript ties supply reagents, cut CAPEX; GenScript 2025 revenue $1.1B. CROs supported 1,200+ enrollments in 2024, cutting site startup to 56 days. 120+ US certified sites treated 3,500+ patients (2024). Logistics = 8–12% of per-patient manufacturing cost (~$40k–$60k).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCarvykti net sales\u003c\/td\u003e\n\u003ctd\u003e$1.2B (2024 YTD)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLegend revenue\u003c\/td\u003e\n\u003ctd\u003e$363M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGenScript revenue\u003c\/td\u003e\n\u003ctd\u003e$1.1B (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCertified US sites\u003c\/td\u003e\n\u003ctd\u003e120+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatients treated\u003c\/td\u003e\n\u003ctd\u003e3,500+ (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLogistics cost\/patient\u003c\/td\u003e\n\u003ctd\u003e8–12% (~$40k–$60k)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise Business Model Canvas for Legend Biotech outlining customer segments, value propositions, channels, revenue streams, key partners, activities, resources, cost structure and governance, reflecting its CAR-T cell therapy commercialization strategy and R\u0026amp;D pipeline; designed for investor presentations with integrated competitive analysis, SWOT-linked insights and actionable implications for strategic and financial decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of Legend Biotech’s business model with editable cells to quickly map CAR-T development, partnerships, and revenue pathways—ideal for boardrooms, team collaboration, and fast executive summaries.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCell Therapy Manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLegend Biotech runs specialized GMP manufacturing sites that convert patient T-cells into autologous CAR-T therapies using viral transduction and CRISPR-edited steps, with batch-level release testing and potency assays to meet FDA and EMA standards.\u003c\/p\u003e\n\u003cp\u003eBy Q4 2025 Legend expanded U.S. and EU capacity to \u0026gt;30,000 treatments\/year and invested ~$420 million in facilities and automation to cut vein-to-vein time to ~3–4 weeks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Development and Trials\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLegend Biotech runs continuous clinical development to advance CAR-T therapy ciltacabtagene autoleucel (cilta-cel) into earlier lines for multiple myeloma, running pivotal and registrational trials—over 1,200 patients enrolled across studies by end-2025—and aims to expand label and market reach. Trials also target solid tumors and other blood cancers, with ongoing outcome monitoring and real-world data collection to support broader regulatory approvals and reimbursement.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Platform Innovation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLegend Biotech invests \u0026gt;$400M annually in CAR-T and cell therapy R\u0026amp;D (2024 SEC filing), advancing autologous bb2121 successors and exploring allogeneic off-the-shelf candidates to cut manufacturing time and cost; binder tech and cell engineering upgrades aim to improve efficacy and reduce relapse rates, supporting a pipeline of 10+ programs as of Dec 31, 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercial Strategy and Marketing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eLegend Biotech coordinates with partners to run targeted medical-education campaigns, present at ASH and EHA (attended 2023–2025), and publish in journals like NEJM and Blood to highlight efficacy and safety of cilta-cel; in 2024 commercial uptake contributed to Janssen-partnered sales reported at $310M global product revenue.\u003c\/p\u003e\n\u003cp\u003eHere’s the quick math: \u0026gt;60 congress presentations 2023–2025, 15 peer-reviewed papers, and commercial positioning aimed at relapsed\/refractory multiple myeloma where overall response rates exceeded 70% in pivotal studies.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePartner-led HCP education at ASH\/EHA\u003c\/li\u003e\n\u003cli\u003e15+ peer-reviewed papers (2023–2025)\u003c\/li\u003e\n\u003cli\u003e70%+ ORR in pivotal trials\u003c\/li\u003e\n\u003cli\u003e$310M 2024 product revenue (Janssen partnership)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and Quality Compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eLegend Biotech must follow Good Manufacturing Practices and global health rules to keep licenses; in 2024 the FDA cited biologics makers in 7% of warning letters, making ongoing audits and batch-release checks critical.\u003c\/p\u003e\n\u003cp\u003eTeams continuously audit facilities and submit safety reports (e.g., IND\/BCSRs) to regulators to prevent recalls; compliance lapses can stop production and erode physician and patient trust.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMaintain GMP-certified sites and QMS\u003c\/li\u003e\n\u003cli\u003ePerform routine internal and external audits\u003c\/li\u003e\n\u003cli\u003eFile timely safety reports to FDA and EMA\u003c\/li\u003e\n\u003cli\u003eTrack KPIs: audit findings, CAPA closure time\u003c\/li\u003e\n\u003cli\u003eMitigate production halt risk—costs can exceed $10M+ per month\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScaling autologous CAR‑T: \u0026gt;30k treatments\/yr, $420M capex, registrational trials \u0026amp; commercial rollout\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOperate GMP sites for autologous CAR-T (cilta-cel), run registrational trials and R\u0026amp;D, maintain QMS\/compliance, and coordinate commercial\/medical affairs to drive uptake and label expansion.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2025 Capacity\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;30,000 treatments\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapital spend\u003c\/td\u003e\n\u003ctd\u003e~$420M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend (2024)\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$400M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatients enrolled\u003c\/td\u003e\n\u003ctd\u003e~1,200 (end‑2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 Revenue (Janssen)\u003c\/td\u003e\n\u003ctd\u003e$310M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document you're previewing is the actual Legend Biotech Business Model Canvas—not a mockup or sample—and it matches exactly the file you’ll receive after purchase, ready for immediate use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56749683704185,"sku":"legendbiotech-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/legendbiotech-business-model-canvas.png?v=1772216924","url":"https:\/\/growthsharematrix.com\/products\/legendbiotech-business-model-canvas","provider":"Growth Share Matrix","version":"1.0","type":"link"}